<DOC>
	<DOC>NCT00178269</DOC>
	<brief_summary>The purpose of this study is to find out how effectively cervix cancer is controlled when radiation is combined with low-dose chemotherapy (Taxotere) . The use of low-dose Taxotere, once per week, with radiation is a new treatment for cervical cancer. This study will also see how well this treatment regimen can be tolerated.</brief_summary>
	<brief_title>Low-Dose TaxotereÂ® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologic confirmation of squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix including FIGO (International Federation of Gynecologists and Obstetricians) stage IB to IVA with or without pelvic adenopathy. No evidence of paraaortic or distant metastases. Must have evaluable disease. Zubrod Performance Status 02 or Karnofsky Performance Status &gt; 60 Laboratory values must be as follows: White blood cell count: &gt; 3,000/mm3,Absolute granulocyte count: &gt; 1,500/mm3, Hemoglobin &gt; 8.0 g/dl, Platelets: &gt; 100,000/mm3, Serum creatinine: &lt; 2.5 mg/dl, Serum calcium: &lt; 1.3 x institutional upper normal limit,Hepatic criteria as follows: Total Bilirubin &lt; ULN for the institution, Signed studyspecific informed consent p Age &gt; 18 years. Peripheral neuropathy must be &lt; grade 1. Prior or simultaneous malignancies (other than skin cancer) unless diseasefree Medical illness preventing the use of taxanebased chemotherapy. Carcinoma of the cervix with the following histology: melanoma, sarcoma, small carcinoid, glassy cell, clear cell, and adenoid cystic. Previous or current medical or psychiatric illness that would prevent informed consent Patients known to be infected with HIV or a history of AIDS are excluded. Prior surgery for carcinoma of the cervix other than a biopsy. Patients with paraaortic disease. Previous pelvic radiation therapy or systemic chemotherapy is not permitted. Women who are pregnant or breastfeeding are excluded from this study. Previous history of hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80 must be excluded.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>